Nomura Holdings’s BridgeBio Pharma BBIO Stock Holding History

Nomura Holdings’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.88M	Sell	92,600 -12,400	-12%	-$899K	0.02%	547
2025 Q4	$8.03M	Sell	105,000 -4,500	-4%	-$295K	0.01%	614
2025 Q3	$5.69M	Buy	109,500 +100,400	+1,103%	+$4.9M	0.01%	718
2025 Q2	$393K	Sell	9,100 -149,500	-94%	-$5.44M	﹤0.01%	1182
2025 Q1	$5.48M	Buy	158,600 +62,600	+65%	+$2.11M	0.01%	679
2024 Q4	$2.63M	Buy	+96,000	New	+$2.48M	﹤0.01%	1004
2023 Q3	–	Sell	-72,900	Closed	-$1.25M	–	1378
2023 Q2	$1.25M	Buy	+72,900	New	+$1.1M	﹤0.01%	848

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nomura Holdings's BBIO Position: Q1 2026 in Review

Nomura Holdings increased its BridgeBio Pharma (BBIO) stake by 2.8% in Q1 2026, buying an estimated $626K and bringing the position to 318,563 shares worth $23.7M. The position accounts for 0.06% of the portfolio, ranked #208.

Nomura Holdings first reported a position in BBIO in Q3 2020 and has held it in 23 quarters since. The position peaked at $23.7M in Q4 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Nomura Holdings held 318,563 shares of BridgeBio Pharma worth $23.7M as of Q1 2026.
Nomura Holdings bought 8,633 BridgeBio Pharma shares in Q1 2026, an estimated $626K.
BridgeBio Pharma made up 0.06% of Nomura Holdings's portfolio in Q1 2026, its #208 holding.
Nomura Holdings first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 23 quarters since.
Nomura Holdings's BridgeBio Pharma position peaked at $23.7M in Q4 2025.
458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.